explore -WSS

explore

author：entertainment 2025-08-23 08:52:51 - browse：24

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： FDA approves RSV monoclonal antibody for infants, toddlers

WSS

Group opposing PBM reform sets lobbying record

How Medicaid coverage policies for immigrants impact new moms

Texas Medical Board asked to define abortion emergency exception

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Unique patient identifier: Experts argue the benefits, pitfalls

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Medical records are filled with copy

Unique patient identifier: Experts argue the benefits, pitfalls

Sports medicine is finally prioritizing gender equality

340B reform proposal comes out of Senate working group

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

AI can’t replace a physician’s gut feeling

Hepatitis C has a cure — but many Americans still lack access to it

Medicare Advantage plans can’t deny care with AI, CMS warns

focus

Bernie brings in new pharma CEOs to talk drug prices

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

At Orexo, a ‘turning point’ for everything but digital health

At Orexo, a ‘turning point’ for everything but digital health

Startup Neumora takes a novel depression drug to Phase 3

Group opposing PBM reform sets lobbying record

Wikipedia

focus

focus

explore